Edition:
India

Mylan NV (MYL.OQ)

MYL.OQ on NASDAQ Stock Exchange Global Select Market

41.73USD
11:08pm IST
Change (% chg)

$0.39 (+0.94%)
Prev Close
$41.34
Open
$41.38
Day's High
$41.93
Day's Low
$40.97
Volume
329,920
Avg. Vol
1,847,687
52-wk High
$47.81
52-wk Low
$29.44

Select another date:

Tue, Feb 20 2018

BRIEF-Mylan Receives Tentative Approval For Combination HIV Treatment DTG/FTC/TAF Under FDA's Pepfar Program

* MYLAN RECEIVES TENTATIVE APPROVAL FOR COMBINATION HIV TREATMENT DTG/FTC/TAF UNDER FDA'S PEPFAR PROGRAM

BRIEF-Mylan Expands Access To HIV/AIDS Medicines With Launch Of First Generic Sustiva Tablets

* MYLAN EXPANDS ACCESS TO HIV/AIDS MEDICINES WITH LAUNCH OF FIRST GENERIC SUSTIVA® TABLETS

BRIEF-Theravance Biopharma And Mylan Announce FDA Acceptance Of New Drug Application For Revefenacin

* THERAVANCE BIOPHARMA AND MYLAN ANNOUNCE FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR REVEFENACIN (TD-4208) IN ADULTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

BRIEF-Theravance, Mylan Announce FDA Acceptance Of Marketing Application For Revefenacin

* THERAVANCE BIOPHARMA AND MYLAN ANNOUNCE FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR REVEFENACIN (TD-4208) IN ADULTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE Source text for Eikon: Further company coverage:

BRIEF-Mylan And Biocon Receive Positive CHMP Opinion For Semglee, Biosimilar Insulin Glargine

* MYLAN AND BIOCON RECEIVE POSITIVE CHMP OPINION FOR SEMGLEE™, BIOSIMILAR INSULIN GLARGINE

BRIEF-Tax reform relatively neutral for Mylan-CFO

* SAYS ITS BIOSIMILAR FOR AMGEN'S NEULASTA COULD BE A "MID-YEAR OPPORTUNITY"

BRIEF-Mylan To Complete $1 Billion Share Repurchase Plan

* MYLAN - AS PER AGREEMENT WITH ABBOTT RELATED TO ABBOTT EPD DEAL, ABBOTT NOTIFIED MYLAN IT SOLD REMAINING 20.3 MILLION IN MYLAN SHARES PRIOR TO YEAR-END​ Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

BRIEF-Momenta And Mylan Announce Development Strategy For Proposed Biosimilar To Eylea

* MOMENTA AND MYLAN ANNOUNCE DEVELOPMENT STRATEGY FOR M710, A PROPOSED BIOSIMILAR TO EYLEA® (AFLIBERCEPT)

FDA approves Mylan's copy of Allergan's vaginal cream

Mylan NV said the U.S. Food and Drug Administration had granted it the approval for a generic version of Allergan's Estrace cream for vaginal atrophy.

FDA approves Mylan's copy of Allergan's vaginal cream

Dec 29 Mylan NV said the U.S. Food and Drug Administration had granted it the approval for a generic version of Allergan's Estrace cream for vaginal atrophy.

Select another date: